Candesartan
- Generic Name
- Candesartan
- Brand Names
- Atacand, Atacand Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N6O3
- CAS Number
- 139481-59-7
- Unique Ingredient Identifier
- S8Q36MD2XX
- Background
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
- Indication
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction an...
- Associated Conditions
- Hypertension, NYHA Functional Class II-IV Heart Failure
- Associated Therapies
- -
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 415
- Registration Number
- NCT02332824
Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02261116
Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02254447
- Locations
- 🇮🇳
GSK Investigational Site, Hyderabad, India
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 18113
- Registration Number
- NCT02211638
Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14151
- Registration Number
- NCT02166697
Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 40
- Registration Number
- NCT02079506
- Locations
- 🇰🇷
Chungnam National University Hospital, Jung-gu, Daejeon, Korea, Republic of
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Bayer
- Registration Number
- NCT02047019
- Locations
- 🇮🇹
AAS 3 Friuli Alto Medio Collin, Udine, Friuli-Venezia Giulia, Italy
🇮🇹IRCCS Ist Neurologico Mediterraneo, Isernia, Molise, Italy
🇮🇹Fondazione Università G.D'Annunzio, Chieti, Abruzzo, Italy
CAndesartan vs LIsinopril Effects on the BRain
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 176
- Registration Number
- NCT01984164
- Locations
- 🇺🇸
Emory Univeristy, Atlanta, Georgia, United States
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT01976572
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, Springfield House Hyde Street, United Kingdom
RAS Quantification in Patients With Aliskiren or Candesartan
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 24
- Registration Number
- NCT01827202
- Locations
- 🇦🇹
Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.